#hematologic malignancy — Tuesday, February 17, 2026 (1 items)
| 0 | 💬 0 |
Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5(+) hematological malignancies.
(linkinghub.elsevier.com)
|
Cell Reports Medicine 2026-02-17 | #immunotherapy #car-t #toxicity #genome editing #hematologic malignancy |